NEO

NeoGenomics, Inc.

17.38

USD

-0.55

-3.07%

Oct 30, 16:00 UTC -4

Closed

After-Market

17.13

-0.25

-1.43%

NeoGenomics, Inc. (NEO) Earnings

NEO Earnings Reports

Positive Surprise Ratio

NEO beat 39 of 44 last estimates.

89%

Next Report

Date of Next Report

Feb 15, 2027

Estimate for Q4 26 (Revenue/ EPS)

$212.10M

$0.06

Implied change from Q3 26 (Revenue/ EPS)

+1.36%

-14.29%

Implied change from Q4 25 (Revenue/ EPS)

+11.53%

NeoGenomics, Inc. earnings per share and revenue

On Oct 28, 2026, NEO reported earnings of 0.07 USD per share (EPS) for Q3 26, beating the estimate of 0.05 USD, resulting in a 27.50% surprise. Revenue reached 209.25 million, compared to an expected 209.40 million, with a -0.07% difference. The market reacted with a -0.33% price change (close before vs. close after earnings).

Looking ahead to Q4 26, -- analysts forecast an EPS of 0.06 USD, with revenue projected to reach 212.10 million USD, implying an decrease of -14.29% EPS, and increase of 1.36% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Ligand Pharmaceuticals Inc.

Report Date

Oct 29, 2026 For Q3 26

Estimate

$2.42

Actual

$2.67

Surprise

+9.91%

AstraZeneca PLC

Report Date

Oct 30, 2026 For Q3 26

Estimate

$2.66

Actual

$2.79

Surprise

+4.56%

Gilead Sciences Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

$2.24

Actual

$2.54

Surprise

+13.66%

Bristol-Myers Squibb Co.

Report Date

Oct 29, 2026 For Q3 26

Estimate

$1.20

Actual

$1.35

Surprise

+11.66%

Regeneron Pharmaceuticals Inc

Report Date

Oct 30, 2026 For Q3 26

Estimate

$16.47

Actual

$20.07

Surprise

+21.79%

Illumina Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

$1.38

Actual

$1.44

Surprise

+4.18%

Alnylam Pharmaceuticals, Inc.

Report Date

Oct 29, 2026 For Q3 26

Estimate

$1.65

Actual

$16.26

Surprise

+885.34%

Exelixis Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

$0.81

Actual

$0.94

Surprise

+15.64%

Kymera Therapeutics, Inc. Common Stock

Report Date

Oct 29, 2026 For Q3 26

Estimate

-$1.29

Actual

-$1.32

Surprise

-2.17%

NovoCure Limited Ordinary Shares

Report Date

Oct 29, 2026 For Q3 26

Estimate

-$0.24

Actual

-$0.09

Surprise

+63.88%

FAQ

What were NeoGenomics, Inc.'s earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, NeoGenomics, Inc. reported EPS of $0.07, beating estimates by 27.5%, and revenue of $209.25M, -0.07% below expectations.

How did the market react to NeoGenomics, Inc.'s Q3 2026 earnings?

The stock price moved down -0.33%, changed from $17.99 before the earnings release to $17.93 the day after.

When is NeoGenomics, Inc. expected to report next?

The next earning report is scheduled for Feb 15, 2027.

What are the forecasts for NeoGenomics, Inc.'s next earnings report?

Based on -- analysts, NeoGenomics, Inc. is expected to report EPS of $0.06 and revenue of $212.10M for Q4 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.